Advertisement

A complex interaction between antitubercular treatment and acenocoumarol

  • Saibal Das
  • Sapan Kumar Behera
  • Kirubakaran Ramakrishnan
  • Mahalakshmi Ganesapandian
  • Hemachandren Munuswamy
  • Sandhiya SelvarajanEmail author
Letter to the Editor
  • 11 Downloads

A 38-year-old female patient underwent aortic valve replacement and Bentall procedure for aortic dissection and aneurysm of the aorta in 2007. Since then, she was on a stable dose of oral anticoagulant [acenocoumarol (ACN), 7−14 mg weekly along with dietary restrictions (avoidance of vitamin K-containing foods) to maintain the international normalized ratio (INR) within 2.5−3.5 [1]. In January 2018, she was diagnosed with lupus vulgaris for which antitubercular treatment (ATT) was planned. The ATT regimen consisted of an induction phase (combination of isoniazid, 225 mg; rifampicin, 450 mg; ethambutol, 1200 mg; and pyrazinamide, 825 mg once daily) of 2 months followed by a maintenance phase (combination of isoniazid, 225 mg, and rifampicin, 450 mg, once daily) of 4 months. Clinical pharmacology opinion was sought for ACN dose adjustment before initiation of ATT because of the potential drug-drug interactions. The patient was followed up for a period of almost 10 months from the point...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent of the patient

Informed consent of the patient was obtained for publishing this case report.

References

  1. 1.
    Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH (2012) Antithrombotic and thrombolytic therapy for valvular disease. Chest 141(2 Suppl):e576S–e600SCrossRefGoogle Scholar
  2. 2.
    Shibata S, Takahashi H, Baba A, Takeshita K, Atsuda K, Matsubara H, Echizen H (2017) Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: report of two cases. Int J Clin Pharmacol Ther 55(5):449–452CrossRefGoogle Scholar
  3. 3.
    Thijssen HH, Flinois JP, Beaune PH (2000) Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos Biol Fate Chem 28(11):1284–1290PubMedGoogle Scholar
  4. 4.
    Chen Y, Ferguson SS, Negishi M, Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308(2):495–501CrossRefGoogle Scholar
  5. 5.
    Wen X, Wang J-S, Neuvonen PJ, Backman JT (2002) Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57(11):799–804CrossRefGoogle Scholar
  6. 6.
    Lee SY, Jang H, Lee J-Y, Kwon K, Oh SJ, Kim SK (2014) Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett 229(1):33–40CrossRefGoogle Scholar
  7. 7.
    Nishimura Y, Kurata N, Sakurai E, Yasuhara H (2004) Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 96(3):293–300CrossRefGoogle Scholar
  8. 8.
    George M, Shewade DG, Kumar SV, Adithan C (2012) Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian J Pharm 44(4):485–488CrossRefGoogle Scholar
  9. 9.
    Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, Kristensen M (1985) Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 20(4):323–326CrossRefGoogle Scholar
  10. 10.
    Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9(5):384–394CrossRefGoogle Scholar
  11. 11.
    Harmsze AM, Deneer VHM, Wiltink EH (2007) Prolonged diminished effect of coumarin derivatives after use of rifampicin. Ned Tijdschr Geneeskd 151(35):1945–1949PubMedGoogle Scholar
  12. 12.
    Michot F, Bürgi M, Büttner J (1970) Rimactan (rifampicin) and anticoagulant therapy. Schweiz Med Wochenschr 100(13):583–584PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical PharmacologyJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PuducherryIndia
  2. 2.Department of Cardiothoracic and Vascular SurgeryJawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)PuducherryIndia

Personalised recommendations